Elegen: DNA Synthesis And Production Company Secures $35 Million
By Amit Chowdhry ● May 22, 2024
Elegen, a leader in next-generation DNA synthesis and production, announced a Series B financing of $35 million led by Triatomic Capital. Also joining the round include strategic investors GSK - which also entered a collaboration and licensing agreement with Elegen to use their proprietary cell-free DNA manufacturing technology in developing GSK’s vaccines and medicines, and John Ballantyne (co-founder of Aldevron). Elegen’s existing investors - including Andreessen Horowitz (a16z) Bio + Health, KdT Ventures, 8VC, Digitalis Ventures, ACVC Partners, Alix Ventures, AME Cloud Ventures and Agilent Technologies - also joined.